












There are a number of pathophysiological causes for a normal or raised CD4 count in the context of progressive HIV infection. These include 
various co-infections, previous splenectomy, and lymphoproliferative disorders. Such circumstances can both confound HIV diagnosis and delay 
initiation of chemoprophylaxis and highly active antiretroviral therapy (HAART). We describe the case of a patient co-infected with HIV and 
human T-cell lymphotropic virus type 1 (HTLV-1) who, prior to HAART initiation, was found to have progressive immune deficiency associated 
with a raised CD4 count. 
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A 51-year-old married man 
from Gauteng province, 
South Africa (SA), originally 
from the Northern Cape, 
tested HIV-positive on an 
enzyme-linked immunosorbent assay (ELISA) 
in March 2002 as part of a routine medical 
examination for insurance purposes. His CD4+ 
count was 794 cells/μl and his HIV viral load 
was 19 365 copies/ml. He gave no history of 
any infectious diseases, but was receiving 
treatment for hypertension. On examination 
he was generally healthy, with normal vital 
signs and all systems proved unremarkable. On 
account of being asymptomatic with a CD4+ 
count within normal range, he was neither 
initiated on highly active antiretroviral therapy 
(HAART) nor chemoprophylaxis, and was told 
to follow-up with his general practitioner for 
regular immune monitoring (Table 1).
An abnormally high CD4+ count was 
detected on follow-up in September 2002 
prompting T-cell receptor polymerase chain 
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evidence of a clonal T-cell lymphoproliferative disorder. A bone-
marrow biopsy was also performed and showed non-malignant T-cell 
hyperplasia. No further studies were conducted and expert opinion 
from HIV clinicians recommended that no antiretroviral therapy (ART) 
be given at that stage.
In January 2009 the patient was referred to us with a history of 
weight loss, fatigue and night sweats. On examination, he had increased 
reflexes affecting the right leg, with weakness in both arms; otherwise, 
examination was essentially normal. Magnetic resonance imaging of 
the spine revealed a collapsed vertebra at T9; a biopsy showed a chronic 
inflammatory process but no granulomata. On account of the history 
and clinical presentation, spinal tuberculosis (TB) was considered 
and TB treatment was commenced. Furthermore, despite the high 
CD4+ count, it was felt that the patient would benefit from ART on 
account of being clinically immune-compromised and having a high 
HIV viral load. He was initiated on a regimen of Truvada (tenofovir/
emtricitabine) and efavirenz (EFV) to which he responded well with a 
drop in RNA copies/ ml of >2 log10 after three months of treatment and 
an undetectable HIV viral load six months thereafter. As the CD4+ count 
remained above normal limits, repeat bone marrow and flow cytometry 
studies were carried out, identifying a population of T-lymphocytes 
with abnormal flow characteristics. T-cell receptor PCR showed the 
presence of a clonal cell population and bone marrow histology revealed 
infiltration by tumour cells with scattered atypical uninucleated cells 
and binucleated Reed-Sternberg cells. Immunophenotypic analysis 
showed no overt evidence of a B-cell lymphoproliferative disorder. 
Antibodies to human T-cell lymphotropic virus type 1/2 (HTLV-
1/2) were detected by ELISA and the patient was diagnosed with 
a smouldering type of adult T-cell leukaemia/lymphoma (ATLL) 
secondary to HTLV-1 infection (HTLV-2 not being associated with this 
condition). He was treated with four cycles of infusional chemotherapy 
consisting of etoposide, vincristine, doxorubicin, cyclophosphamide 
and prednisone (EPOCH), which he tolerated well. Interferon-alpha 
therapy was subsequently commenced and mantained three times 
per week. At the time of writing, the patient is clinically well with no 
neurological deficits, an undetectable HIV viral load and a CD4+ count 
of 4 430 cells/μl.
Discussion
HTLV-1 was the first retrovirus to be identified in humans and is 
structurally related to other viruses within the retroviridae family, such 
as HIV-1 and HIV-2, sharing similar routes of transmission. Since its 
discovery in 1979 three additional human deltaretroviruses (HTLV-2, 
HTLV-3 and HTLV-4) have been found, but only HTLV-1 and HTLV-2 
have so far been associated with human disease. Antibodies to HTLV-
1 were first identified in SA in 1984 and the first report of isolation 
of the virus was published in 1988. [1,2] Subsequently, a number of 
seroprevalence studies have been conducted in SA, where HTLV-1 has 
been found to be endemic in areas of Mpumalanga, the Eastern Cape, 
Free State and KwaZulu-Natal (KZN). [3,4] However, there are no recent 
representative data regarding prevalence in the general SA population 
or specific patient subgroups.[5] 
Like other human retroviruses, HTLV-1 causes a lifelong infection 
of T-lymphocytes, in particular CD4+ cells. However, unlike HIV, 
the immunological hallmark of HTLV-1-infected individuals is a 
sustained proliferation of T-cells driven by the HTLV-1-encoded Tax 
protein. [6] The subsequent transactivation of cellular genes by the Tax-
encoded region can result in malignant transformation, although this 
is rare.[7] In the majority of cases, cytotoxic T-cells effectively control 
the virus by lysis of infected lymphocytes, which in turn results in 
the release of inflammatory cytokines that can be pathogenic.[6] On 
account of these various pathophysiological mechanisms, HTLV-1 
is associated with a diverse range of pathology, including malignant 
disease, inflammatory syndromes and infective complications.[6] A 
number of these conditions have been described in SA, including ATLL, 
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/
TSP) and infectious dermatitis.[8-10] Although the life-time risk for 
HTLV-1-associated diseases in general is considered close to 10%, an 
indication of a long history of viral-human co-evolution,[6] this may 
be an under-representation when the interaction between HTLV-1 
and other infective agents is considered. TB has been found to occur 
more frequently in patients infected with HTLV-1 and is also thought 
to be associated with a worse prognosis. [6] HTLV-1 has been shown to 
up-regulate hepatitis C viral replication and is implicated as a co-factor 
in the development of hepatocellular carcinoma. Furthermore, two 
studies have demonstrated an increased rate of cervical carcinoma in 
HTLV-1-infected patients.[7] Whether HIV-1 co-infection with HTLV-1 
is associated with a faster progression to AIDS remains a contentious 
issue, although a number of studies have suggested as much. [11] What is, 
however, less controversial and perhaps of greater relevance is the effect 
of HTLV-1 on T-lymphocytes, and in particular, its association with 
CD4+ lymphocytosis in HIV-1 co-infected patients.[12,13]
Table 1. CD4+ and HIV viral load monitoring (2002 - 2009)
Date CD4+ count (cells/μl) CD4+ (%) HIV-1 viral load (copies/ml)
March 2002 794 15.0 19 365
September 2002 6 043 15.6 59 900
March 2003 4 891 13.9 31 400
September 2003 7 775 17.0 37 200
November 2003 7 799 21.0 58 300
June 2004 5 893 15.0 252 000
April 2006 13 820 23.1 133 281
September 2008 12 731 23.6 1 226 897
January 2009 2 875 73.0 494 510
April 2009 6 939 72.0 1 920
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In general, lymphocytosis can be classified 
as belonging to one of two groups: either a 
reactive polyclonal proliferation, which can be 
caused by a variety of infective agents, hyper-
sensitivity reactions, autoimmune conditions 
and splenectomy, or a clonal expansion as a 
result of a lymphoproliferative disorder. In 
the context of HIV co-infection, lympho-
cytosis has been described during early sero-
conversion associated with CMV, as well as 
in HIV/HTLV-1 co-infection where CD4+ 
lymphocytosis can be caused by both a reactive 
or clonal expansion. Consequently, patients 
with untreated HIV-1 who are co-infected 
with HTLV-1 show a dissociation between 
immunological and virological markers. That 
is to say, HIV-1/HTLV-1 co-infected patients 
have been found to progress to AIDS with a 
high HIV viral load, but in the presence of a 
normal or higher than normal CD4+ count 
(both absolute and percentage).[12] A recent 
study in Mozambique demonstrated that 
co-infected pre-HAART adult patients were 
seven times more likely to have CD4+ counts 
>500 cells/μl (median 525 cells/μl) than HIV 
mono-infected patients.[13] However, as these 
CD4+ cells are likely to be functionally altered, 
associated with a loss of naive cells and a 
higher activation pattern, CD4+ lymphocyte 
counts in HIV-1/ HTLV-1 co-infected patients 
cannot be considered to be a reliable marker of 
immunological competence.[12] Furthermore, 
CD4+ counts can be dramatically raised on 
account of ATLL (i.e. clonal expansion), which 
occurs in ≤5% of HTLV-1 infections.[6] As most 
cases of ATLL develop in individuals infected 
early in life through breastfeeding,[6] it is 
probable that our patient was already infected 
with HTLV-1 when he first presented in 2002 
with a CD4+ count of 794 cells/μl. Whether 
initiation of HAART at this juncture would 
have prevented the development of ATLL 
cannot be determined. However, it is thought 
that zidovudine (AZT) may protect HTLV-
1-infected peripheral blood mononuclear 
cells from immortalisation on account of its 
genotoxic/mutagenic properties. [14]
The last sizeable HTLV-1 seroprevalence 
study in SA was conducted in northern KZN 
in 1993; a prevalence of 2.6% was found among 
the general population.[4] In the same study an 
HIV-1 prevalence of 3.5% was noted. As the 
risk factors for HTLV-1 and HIV are shared, 
an epidemiological association between these 
two retroviruses is to be expected. In 1996, 
HTLV-1 was found in 2% of asymptomatic 
urban black people in the Free State, but in 6% 
of HIV-seropositive patients from the same 
region.[3] More recently, and alarmingly, in a 
small retrospective study of 170 HIV-positive 
plasma specimens collected between 2007 and 
2008 from Limpopo, 24% of specimens tested 
positive for HTLV-1/2 antibodies by ELISA. [15] 
Unfortunately, further testing to confirm the 
diagnosis or differentiate between HTLV-1 
and HTLV-2 infection was not performed. 
Nevertheless, these findings highlight the 
evident gap in current knowledge and the 
need for clinicians to be aware of retroviruses 
other than just HIV. 
Conclusion
A CD4+ lymphocyte count cannot always 
be considered to be a reliable marker of 
immunological competence in HIV-infected 
people, especially in patients co-infected with 
HTLV-1. Normal or raised CD4+ counts in 
such persons can be on account of reactive or 
clonal expansion of T-lymphocytes and can 
confound HIV diagnosis and delay initiation 
of chemoprophylaxis and HAART. As we lack 
up-to-date epidemiological data but know that 
certain areas in SA are endemic for HTLV-1, we 
suggest maintaining a high index of suspicion 
of HTLV-1 infection in all HIV-positive adult 
patients in Southern Africa. In particular, HIV-
positive persons who are clinically immune-
compromised and have a raised CD4+ count 
should be tested for HTLV-1, as well as patients 
who present with clinical features in keeping 
with ATLL, HAM/TSP or infective dermatitis. 
As locally available serological tests are unable to 
differentiate HTLV-1 and -2, a PCR or western 
blot analysis may be required subsequent to a 
positive HTLV-1/2 ELISA test to confirm the 
diagnosis and distinguish between HTLV-1 
and -2. Furthermore, the decision to initiate 
HAART in co-infected patients is better 
determined by clinical stage and HIV viral load 
than CD4+ count. 
More research is needed to understand the 
epidemiology of HTLV-1 infection in Southern 
Africa; not only with regard to co-infections 
such as HIV-1/ HTLV-1 and TB/ HTLV-1, but 
also in terms of the wider public health impact, 
including implications for PMTCT practices 
and safety of the blood supply. 
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